Home cancer injections: a new hope for myeloma patients?
NCT ID NCT06015542
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study is testing if people with relapsed multiple myeloma can safely inject the drug elranatamab at home instead of going to a clinic. Twenty participants will learn to self-administer the injections and track side effects, time spent, and quality of life. The goal is to see if home treatment is safe, practical, and preferred by patients and caregivers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Heamatology
RECRUITINGVejle, 7100, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Odense University Hospital
RECRUITINGOdense, 5000, Denmark
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Elranatamab (a drug injected under the skin)
What this could lead to
If successful, this could allow multiple myeloma patients to safely receive treatment at home instead of traveling to a clinic, improving convenience and quality of life.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply to all patients. Self-administration carries risks of side effects like cytokine release syndrome or infections, and some doses may need to be given in clinic.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.